Akebia Therapeutics, Inc.
AKBA
$1.44
$0.021.06%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1.95% | -5.93% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.95% | -5.93% | |||
| Cost of Revenue | 6.36% | -4.07% | |||
| Gross Profit | -3.71% | -6.32% | |||
| SG&A Expenses | -10.33% | 9.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.22% | 12.50% | |||
| Operating Income | -235.94% | -68.64% | |||
| Income Before Tax | -1,072.73% | 367.61% | |||
| Income Tax Expenses | 64.07% | -- | |||
| Earnings from Continuing Operations | -2,367.41% | 118.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2,367.41% | 118.62% | |||
| EBIT | -235.94% | -68.64% | |||
| EBITDA | -220.14% | -67.14% | |||
| EPS Basic | -2,405.00% | 122.22% | |||
| Normalized Basic EPS | -862.96% | 237.50% | |||
| EPS Diluted | -2,590.00% | 122.22% | |||
| Normalized Diluted EPS | -892.31% | 225.00% | |||
| Average Basic Shares Outstanding | 0.22% | 0.85% | |||
| Average Diluted Shares Outstanding | -3.28% | 1.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||